Phase 1 Clinical Trial to Evaluate the Safety of FURESTEM-CD Inj. in Patients With Moderate to Severe Plaque-type Psoriasis.

NCT02918123 Phase 1 UNKNOWN

Phase I clinical trial to evaluate safety of FURESTEM-CD Inj. in patients with moderate to severe in plaque-type psoriasis injection for 4weeks.

Details

Lead sponsor	Kang Stem Biotech Co., Ltd.
Phase	Phase 1
Status	UNKNOWN
Enrolment	9
Start date	2018-01-17
Completion	2021-12

Conditions

• Psoriasis

Interventions

• FURESTEM-CD Inj.

Primary outcomes

• number of adverse events — 4 weeks follow-up after treatment
• safety lab tests, physical examination, ECG, vital signs — 4 weeks follow-up after treatment
• variation of Cytokine, PASI, BSA — 4 weeks follow-up after treatment

Countries

South Korea